The Neurobiological Connection Between PTSD and the Sympathetic Nervous System
To understand why a nerve block in the neck might affect PTSD symptoms, it helps to understand what PTSD actually does to the nervous system. The condition is characterized by a persistent state of threat activation — hypervigilance, exaggerated startle responses, intrusive memories, emotional reactivity — that reflects a nervous system that cannot fully return to baseline after trauma.
Research points to abnormal activity in the sympathetic nervous system as a key feature of this dysregulation. In PTSD, the sympathetic branch — the one governing the fight-or-flight response — appears to remain chronically overactivated. The body continues responding as though the threat is ongoing, even when it objectively is not. This isn’t a failure of willpower or cognition; it is a physiological state that talk therapy alone may not be sufficient to normalize.
The stellate ganglion is a sympathetic nerve cluster located in the neck at the level of the cervical vertebrae. One proposed mechanism for its effect on PTSD involves nerve growth factor (NGF), a protein associated with the sprouting of new sympathetic nerve fibers. The theory, supported by researchers including those who conducted early clinical work in military populations, is that trauma drives excess sympathetic nerve growth — increasing the nervous system’s capacity for threat response — and that blocking the stellate ganglion may help normalize that signaling. The anesthetic injection temporarily interrupts the sympathetic circuit, and the clinical benefit observed in trials appears to persist beyond the pharmacological duration of the block.
What the Clinical Evidence Shows
The randomized clinical trial referenced here represents a significant development in the evidence base for SGB as a PTSD intervention. It was a controlled study — not a case series or anecdotal report — and it used the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5), the gold-standard instrument for measuring PTSD symptom severity, as its primary outcome measure. Two injections, two weeks apart, produced measurable reductions in total symptom severity compared to a sham procedure over the eight-week observation period.
This does not mean SGB is a cure for PTSD, or that it replaces psychotherapy or medication management. The evidence supports it as an adjunctive option — a treatment that may reduce symptom burden and potentially improve patients’ capacity to engage with other therapies. For patients with treatment-resistant PTSD who have already worked through first-line options without adequate relief, that distinction matters enormously.
At ReNova Health, we present SGB for PTSD with the evidence framed accurately: it is a studied, procedural option with a plausible biological mechanism and published controlled trial data supporting its use. It is not a guaranteed solution, and results vary by individual. We discuss the evidence — including its limitations — during every consultation.
How the Procedure Is Performed
A stellate ganglion block for PTSD follows the same procedural approach as SGB for pain management. A local anesthetic is injected under imaging guidance — ultrasound or fluoroscopy — into the tissue surrounding the stellate ganglion in the neck. The imaging guidance is essential; the injection site is adjacent to several important vascular structures, and precision matters for both safety and effect.
The procedure is performed on an outpatient basis. Most patients are observed briefly in the clinic following the injection and are able to return home the same day. A common transient sign of a successful block is Horner’s syndrome — temporary drooping of the eyelid and pupil constriction on the injected side — which reflects sympathetic interruption and resolves as the anesthetic wears off.
Based on the clinical trial protocol that demonstrated efficacy, two injections administered two weeks apart is a commonly referenced treatment course. We discuss the appropriate protocol for each patient during the consultation.
Who This May Be Appropriate For — and the Honest Conversation About Barriers
SGB for PTSD is generally considered for patients who meet criteria for PTSD and have not achieved adequate relief from first-line treatments — therapy, medication, or both. It is not intended as a replacement for psychological care but as a complement to it, addressing the physiological component of the condition while other modalities address the psychological and behavioral dimensions.
The two most common barriers we encounter are stigma and cost. On stigma: seeking a procedural treatment for a psychiatric condition can feel like an admission that the psychological approaches haven’t worked, or like a less legitimate path than traditional therapy. We don’t share that view. PTSD has a neurobiological substrate. Addressing that substrate directly is not a shortcut — it is a clinically reasoned option when standard approaches have reached their ceiling. For patients who also face co-occurring substance use challenges alongside their PTSD, we offer a dedicated approach to SGB for co-occurring PTSD and substance use that addresses both dimensions of the sympathetic dysregulation involved.
On cost: insurance coverage for SGB as a PTSD treatment varies and in many cases is limited. We verify coverage before treatment and discuss out-of-pocket costs openly before any decision is made. For patients who have spent years in treatment without adequate relief, the cost conversation is best held in the context of that history, not in the abstract. We are willing to have it directly.
Frequently Asked Questions
Does SGB replace therapy for PTSD? No. The clinical evidence supports SGB as an adjunctive treatment — one that may reduce symptom burden and potentially enhance receptivity to therapy, not replace it. We recommend patients maintain or initiate psychological care alongside the procedure when appropriate. Discuss the full treatment picture with your provider.
How quickly might I notice changes after the injection? Some patients report changes within hours to days following the procedure. The timeline varies by individual. We follow up with patients to track response and use that information to guide decisions about the second injection and any further care.
Is this procedure safe? SGB has a well-established safety profile from decades of use in pain management. When performed under imaging guidance by a trained provider, it is associated with few adverse events. The most common side effects are transient — Horner’s syndrome and mild soreness at the injection site — and resolve without intervention. We review the full risk profile during your consultation.
I’m already on medication for PTSD. Can I still consider this? Yes, in most cases. SGB does not interact with psychiatric medications in a way that would preclude its use. We review your full medication list during the consultation to identify any relevant considerations. Do not adjust or stop any medication without guidance from your prescribing provider.
What if one injection doesn’t produce noticeable results? The published protocol involves two injections two weeks apart, and the clinical benefit observed in the trial reflects that full course. A decision about whether to proceed with the second injection — or to consider the procedure a non-response — is made in conversation with your provider based on your experience after the first.
Key Takeaways
- PTSD involves chronic sympathetic nervous system overactivation — a physiological state that persists independently of the original trauma and may not fully resolve through psychological treatment alone.
- The stellate ganglion block addresses this by temporarily interrupting sympathetic signaling through a cervical nerve cluster involved in the threat-response pathway.
- A randomized controlled trial found two SGB treatments administered two weeks apart produced measurable reductions in PTSD symptom severity scores over eight weeks.
- SGB is an adjunctive option — it may reduce symptom burden and complement psychological care, but it is not a standalone cure and does not replace therapy.
- Results vary by individual. Candidacy is determined through evaluation. Insurance coverage varies and is discussed before any commitment is made.
If PTSD has not responded adequately to the treatments you’ve already tried, the underlying neurobiology may be part of what hasn’t been addressed. Contact ReNova Health to schedule a consultation and find out whether stellate ganglion block is an appropriate option for your situation.
References
National Institutes of Health. Effect of Stellate Ganglion Block Treatment on Posttraumatic Stress Disorder Symptoms: A Randomized Clinical Trial. https://pmc.ncbi.nlm.nih.gov/articles/PMC6865253/
Medical Disclaimer
The information in this blog is provided for educational purposes only and does not constitute medical advice. Stellate ganglion block and other interventional procedures should only be pursued under the supervision of a licensed healthcare provider with full knowledge of your medical and psychiatric history. Individual results vary. Not all patients are candidates — a thorough clinical evaluation is required before any treatment is recommended or performed. If you are experiencing a mental health crisis, please call or text 988 to reach the Suicide and Crisis Lifeline or go to your nearest emergency room. Please consult a qualified provider to discuss your specific condition and options.